
Allovir Inc (KLRS) Stock Forecast & Price Target
Allovir Inc (KLRS) Analyst Ratings
Bulls say
Kalaris Therapeutics Inc. is positioned favorably in the biopharmaceutical market due to its innovative development of TH103, a novel anti-VEGF drug, which demonstrates superior retinal retention compared to current market leader Eylea, potentially translating to longer-lasting therapeutic effects. The strong market performance of similar anti-VEGF drugs, exemplified by Vabysmo's exceeding $4 billion in global sales within three years and capturing significant market share, underscores the potential for substantial revenue growth in this sector. Furthermore, preclinical findings showing TH103's complete inhibition of VEGF-induced endothelial cell proliferation indicate promising efficacy, generating optimism around its advancement through clinical trials and subsequent market introduction.
Bears say
Kalaris Therapeutics Inc., as a development-stage biotechnology company, has not yet commercialized any products and will require substantial infrastructure investments to launch and market its therapeutic candidate, TH103. The company is expected to continue incurring significant net losses until it achieves commercialization, which may be further exacerbated by potential delays in clinical development and regulatory approvals. Additionally, strong competition from both established and emerging therapies poses a risk to Kalaris's market penetration and pricing, which may hinder its financial performance and outlook.
This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.
Allovir Inc (KLRS) Analyst Forecast & Price Prediction
Start investing in Allovir Inc (KLRS)
Order type
Buy in
Order amount
Est. shares
0 shares